...
首页> 外文期刊>Neuromodulation: journal of the International Neuromodulation Society >Multicenter Retrospective Study of Neurostimulation With Exit of Therapy by Explant
【24h】

Multicenter Retrospective Study of Neurostimulation With Exit of Therapy by Explant

机译:浅析治疗疗法疗效的多中心回顾性研究

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction Spinal cord stimulation (SCS) devices are cost effective and improve function as well as quality of life. Despite the demonstrated benefits of SCS, some patients have the device explanted. We are interested in exploring the patient characteristics of those explanted. Methods This is a retrospective chart review of neurostimulation patients who underwent explantation at 18 centers across the United States within the previous five years. Results Data from 352 patients were collected and compiled. Failed Back Surgery syndrome was the most common diagnosis (38.9%; n ?=?136/350) and over half of the patients reported numerical rating scale (NRS) scores ≥8 prior to implant (64.3%; n ?=?207/322). All patients reported changes in NRS scores across time, with an initial decrease after implant followed by a pre‐explant increase ( F (2, 961)?=?121.7, p ??0.001). The most common reason for device explant was lack or loss of efficacy (43.9%; 152/346) followed by complications (20.2%; 70/346). Eighteen percent (18%; 62/343) of patients were explanted by a different physician than the implanting one. Rechargeable devices were explanted at a median of 15 months, whereas primary cell device explants occurred at a median of 36 months (CI 01.434, 2.373; median endpoint time ratio?=?2.40). Discussion Loss or lack of efficacy and complications with therapy represent the most frequent reasons for neurostimulation explantation. Of the devices that were explanted, therapy was terminated earlier when devices were rechargeable, when complications occurred, or when pain relief was not achieved or maintained. Furthermore, in nearly 20% of the cases, a different provider than the implanting physician performed device removal. Conclusions SCS is largely a safe and efficacious strategy for treating select chronic refractory pain syndromes. Further prospective data and innovation are needed to improve patient selection, maintain SCS therapeutic efficacy and reduce the reasons that lead to device explant.
机译:引言脊髓刺激(SCS)设备具有成本效益,提高功能以及生活质量。尽管SCS的效果效益,但有些患者已突出了该装置。我们有兴趣探索探讨的患者特征。方法是对在过去五年内,在美国在美国的18个中心接受突变的神经刺激患者的回顾图审查。从352名患者收集和编制的结果数据。后手术综合征失败是最常见的诊断(38.9%; N?= 136/350),超过一半的患者报告了数值额定尺度(NRS)分数≥8(64.3%; n?= 207 / 322)。所有患者均报告跨时间的NRS分数的变化,植入后的初步减少,然后进行预分析培养型(F(2,961)?= 121.7,p≤≤0.001)。设备外植体的最常见原因缺乏或损失疗效(43.9%; 152/346),然后是并发症(20.2%; 70/346)。由不同的医师突出了18%(18%; 62/343)的患者比植入术。可充电装置在15个月的中位数突出,而原发性细胞器件外植体发生在36个月的中位数(CI 01.434,2.373;中值终点时间比率?=?2.40)。讨论丧失或缺乏治疗的疗效和并发症代表了神经刺激促进的最常见原因。在脱盐的装置的内容中,当在发生并发症时,当使用并发症时,或者当没有达到或维持疼痛缓解时,终止治疗。此外,在近20%的情况下,不同的提供者比植入医师进行的设备去除。结论SCS在很大程度上是一种安全而有效的治疗选择慢性耐火疼痛综合征的策略。需要进一步的预期数据和创新来改善患者选择,维持SCS治疗效果,并降低导致设备外植体的原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号